Stocks
BridgeBio Financial Statements (BBIO) |
||||||||||
| BridgeBiosmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 03.03.2020 | 25.02.2021 | 25.02.2022 | 23.02.2023 | 22.02.2024 | 02.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 40.6 | 8.25 | 69.7 | 77.6 | 9.30 | 218.6 | |||
| Operating Income, bln rub | -266.2 | -474.5 | -579.7 | -471.9 | -607.4 | -477.5 | ||||
| EBITDA, bln rub | ? | -279.4 | -468.8 | -539.7 | -353.7 | -574.6 | -456.5 | |||
| Net profit, bln rub | ? | -260.4 | -483.9 | -639.3 | -494.0 | -643.2 | -538.3 | |||
| OCF, bln rub | ? | -253.6 | -399.7 | -497.9 | -419.5 | -527.7 | -602.9 | |||
| CAPEX, bln rub | ? | 5.14 | 7.52 | 48.2 | 6.32 | 1.31 | 2.79 | |||
| FCF, bln rub | ? | -258.7 | -407.2 | -546.2 | -425.8 | -529.0 | -605.7 | |||
| Dividend payout, bln rub | 0.997 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 304.3 | 482.7 | 646.3 | 546.1 | 606.3 | 688.7 | ||||
| Cost of production, bln rub | 2.50 | 3.09 | 3.11 | 3.43 | 2.45 | 3.69 | ||||
| R&D, bln rub | 209.9 | 337.0 | 454.1 | 402.9 | 455.7 | 504.4 | ||||
| Interest expenses, bln rub | 8.77 | 36.7 | 46.8 | 80.4 | 81.3 | 84.6 | ||||
| Assets, bln rub | 631.7 | 703.6 | 1 013 | 623.0 | 546.4 | 849.3 | ||||
| Net Assets, bln rub | ? | 408.5 | 57.9 | -870.4 | -1 255 | -1 354 | -1 050 | |||
| Debt, bln rub | 99.8 | 495.8 | 1 726 | 1 724 | 1 740 | 1 729 | ||||
| Cash, bln rub | 577.1 | 607.1 | 787.5 | 428.3 | 434.9 | 519.8 | ||||
| Net debt, bln rub | -477.3 | -111.3 | 938.7 | 1 295 | 1 305 | 1 209 | ||||
| Ordinary share price, rub | 35.1 | 71.1 | 16.7 | 7.62 | 40.4 | 26.9 | ||||
| Number of ordinary shares, mln | 105.1 | 118.0 | 144.4 | 147.5 | 162.8 | 178.7 | ||||
| Market cap, bln rub | 3 684 | 8 391 | 2 408 | 1 124 | 6 572 | 4 811 | ||||
| EV, bln rub | ? | 3 206 | 8 279 | 3 347 | 2 419 | 7 877 | 6 020 | |||
| Book value, bln rub | 408 | 58 | -915 | -1 283 | -1 381 | -1 075 | ||||
| EPS, rub | ? | -2.48 | -4.10 | -4.43 | -3.35 | -3.95 | -3.01 | |||
| FCF/share, rub | -2.46 | -3.45 | -3.78 | -2.89 | -3.25 | -3.39 | ||||
| BV/share, rub | 3.89 | 0.49 | -6.34 | -8.70 | -8.48 | -6.02 | ||||
| EBITDA margin, % | ? | -688.9% | -5 684% | -774.1% | -455.5% | -6 177% | -208.8% | |||
| Net margin, % | ? | -642.1% | -5 866% | -917.0% | -636.2% | -6 914% | -246.2% | |||
| FCF yield, % | ? | -7.02% | -4.85% | -22.7% | -37.9% | -8.05% | -12.6% | |||
| ROE, % | ? | -63.8% | -835.7% | 73.4% | 39.4% | 47.5% | 51.3% | |||
| ROA, % | ? | -41.2% | -68.8% | -63.1% | -79.3% | -117.7% | -63.4% | |||
| P/E | ? | -14.1 | -17.3 | -3.77 | -2.27 | -10.2 | -8.94 | |||
| P/FCF | -14.2 | -20.6 | -4.41 | -2.64 | -12.4 | -7.94 | ||||
| P/S | ? | 90.8 | 1 017 | 34.5 | 14.5 | 706.4 | 22.0 | |||
| P/BV | ? | 9.02 | 144.9 | -2.63 | -0.88 | -4.76 | -4.47 | |||
| EV/EBITDA | ? | -11.5 | -17.7 | -6.20 | -6.84 | -13.7 | -13.2 | |||
| Debt/EBITDA | 1.71 | 0.24 | -1.74 | -3.66 | -2.27 | -2.65 | ||||
| R&D/CAPEX, % | 4 086% | 4 483% | 941.3% | 6 374% | 34 894% | 18 106% | ||||
| CAPEX/Revenue, % | 12.7% | 91.1% | 69.2% | 8.14% | 14.0% | 1.27% | ||||
| BridgeBio shareholders | ||||||||||
